(Q35781583)

10 August 2017

1 reference

title

Drug intervention trials in sepsis: divergent results (English)

1 reference

10 August 2017

0 references

Kees H Polderman

1

1 reference

10 August 2017

Armand R J Girbes

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

363

1 reference

10 August 2017

issue

9422

1 reference

10 August 2017

page(s)

1721-1723

1 reference

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

The epidemiology of sepsis in the United States from 1979 through 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Trials stopped early: too good to be true?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

A definite role for treatment with activated protein C in sepsis? Standard use is premature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Interobserver variability in the use of APACHE II scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Accuracy and reliability of APACHE II scoring in two intensive care units Problems and pitfalls in the use of APACHE II and suggestions for improvement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Hospital mortality in relation to staff workload: a 4-year study in an adult intensive-care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

Unraveling severe sepsis: why did OPTIMIST fail and what's next?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2916259-4

7 January 2021

10.1016/S0140-6736(04)16259-4

Identifiers

DOI

1 reference

10 August 2017

1 reference